Eric Shaff is the President and Chief Executive Officer of Seres. Mr. Shaff was previously the Executive Vice President, Chief Operating and Financial Officer of Seres. He has over 20 years of experience working in leadership roles in biotechnology, finance, corporate development, and …

2025年1月16日 · Seres Therapeutics CEO Eric Shaff explains how the company is building on its experience developing VOWST, the first-ever FDA-approved oral life biotherapeutic, as it pioneers new therapies like SER-155 to address unmet need in in allo-HSCT.

Eric Shaff is the President and Chief Executive Officer of Seres. Mr. Shaff was previously the Executive Vice President, Chief Operating and Financial Officer of Seres. He has more than 15 years of experience working in leadership roles in biotechnology finance, corporate development, and capital markets.

Eric Shaff has over 15 years of experience working in leadership roles in biotechnology finance, corporate development, and capital markets. He serves as the President and Chief Executive Officer of Seres Therapeutics, a therapeutics company engaged in the R&D of drugs for the treatment of microbiome diseases.

2019年1月15日 · Seres Therapeutics announces the appointment of Eric D. Shaff as President and Chief Executive Officer. Mr. Shaff succeeds Roger J. Pomerantz, M.D.

2025年1月30日 · Eric D. Shaff is currently the President, Chief Executive Officer & Director at Seres Therapeutics, Inc. He previously served as an Independent Director at Sigilon Therapeutics, Inc. from 2017 to 2023. Eric also worked as a Principal at Pfizer Inc. and as the Global Head-Rare Genetic Disease Finance at Genzyme Corp. from 2004 to 2011.

2024年1月10日 · Seres Therapeutics CEO Eric Shaff discusses the patient impact of VOWST, the first ever approved oral microbiome drug for recurrent C.diff, and why this is only the beginning for the microbiome as a new field of medicine.

Eric Shaff is the current President & CEO at Seres Therapeutics. Eric has also previously worked as Vice President, Corporate Finance at Momenta Pharmaceuticals and as Vice President, Finance at Genzyme Corporation. Most recently, they were Senior Analyst at Broadview Int'l (now Jefferies Broadview).

Eric Shaff, Chief Executive Officer 39th Annual J.P. Morgan Healthcare Conference. January 14, 2021